These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 28924968)

  • 1. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer.
    Usón Junior PLS; Callegaro-Filho D; Bugano DDG; Moura F; Maluf FC
    J Gastrointest Cancer; 2018 Dec; 49(4):481-486. PubMed ID: 28924968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
    Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
    Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
    Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
    Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
    Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
    J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
    Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
    Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
    Medicine (Baltimore); 2018 Jan; 97(4):e9707. PubMed ID: 29369199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
    Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
    BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer.
    Chen Y; Shao Z; Chen W; Xie H; Wu Z; Qin G; Zhao N
    Oncotarget; 2017 May; 8(18):29925-29934. PubMed ID: 28404893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA19-9 for detecting recurrence of pancreatic cancer.
    Azizian A; Rühlmann F; Krause T; Bernhardt M; Jo P; König A; Kleiß M; Leha A; Ghadimi M; Gaedcke J
    Sci Rep; 2020 Jan; 10(1):1332. PubMed ID: 31992753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
    Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
    Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
    Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
    J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.
    Kim YJ; Koh HK; Chie EK; Oh DY; Bang YJ; Nam EM; Kim K
    Int J Clin Oncol; 2017 Dec; 22(6):1069-1075. PubMed ID: 28477059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer.
    Cetin S; Dede I
    J Cancer Res Ther; 2020; 16(4):909-916. PubMed ID: 32930139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer.
    Nakai Y; Isayama H; Sasaki T; Takahara N; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Yamamoto K; Mohri D; Kogure H; Yamamoto N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1291-7. PubMed ID: 24121456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.
    Zhao JG; Hu Y; Liao Q; Niu ZY; Zhao YP
    World J Gastroenterol; 2014 May; 20(19):5875-80. PubMed ID: 24914348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.